Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2007

View Archived Issues

Positive preclinical profile of the CRF1 antagonist MTIP in animal models of alcoholism

Nycomed restructures following Altana Pharma acquisition

MerLion and Merck Banyu enter new drug discovery alliance

VASTox acquires DanioLabs and Dextra Laboratories

Pain Therapeutics in-licenses new technology for treatment of hemophilia

Results from phase I study of AEOL-10150

Dll4 as a novel target for antiangiogenic drugs

Affirmative preclinical profile set BEZ-235 for clinical evaluation

Nilvadipine show positive preliminary results in Alzheimer's

Quinvaxem vaccinations in Ethiopia

Amira raises funding to advance drug candidates through proof of concept

New WHO guidance on pneumococcal vaccines in developing countries

NovaDel Pharma outlines 2007 goals

Hana Biosciences provides pipeline update

New treatment options for metabolic disorders are disclosed in patent literature

Novel therapeutic strategies for the treatment of infection described in recent patents

Synosis Therapeutics changes name to Synosia Therapeutics

Eisai granted rights to Eril in Korea

Genta expects negative European opinion for Genasense in advanced melanoma

EAU's new guidelines recommend Sutent in first-line metastatic RCC

Revlimid recommended for approval in E.U. for multiple myeloma

Altargo recommended for E.U. approval

E.U. recommends approval of Herceptin for new breast cancer indication

Januvia approved in E.U. for type 2 diabetes

Roche files sNDA for XELOX in metastatic colorectal cancer

A-620223 a potent inhibitor of poly(ADP-ribose) polymerase

GlaxoSmithKline identifies GSK-983 as potential human papillomavirus treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...